# Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia

> **NCT02146924** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 71 (actual)

## Conditions studied

- B Acute Lymphoblastic Leukemia
- Recurrent Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
- **BIOLOGICAL:** CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02146924
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-10-16
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-07-15
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02146924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02146924, "Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02146924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*